Amalgamated Financial’s Charles River Laboratories CRL Stock Holding History

Amalgamated Financial’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$5.41M	Buy	+19,054	New	+$5.88M	0.04%	421

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Amalgamated Financial's CRL Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Charles River Laboratories (CRL) in Q1 2022: 19,054 shares worth $5.41M. The stake represents 0.04% of the portfolio and ranks #421 among its holdings.

645 funds tracked by Wall St. Rank hold CRL as of Q1 2022.

Amalgamated Financial held 19,054 shares of Charles River Laboratories worth $5.41M as of Q1 2022.
Charles River Laboratories was a new Amalgamated Financial position in Q1 2022.
Charles River Laboratories made up 0.04% of Amalgamated Financial's portfolio in Q1 2022, its #421 holding.
645 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.